NASDAQ:CBPO - China Biologic Products Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $72.02 -5.01 (-6.50 %) (As of 12/17/2018 01:11 AM ET)Previous Close$72.02Today's Range$71.67 - $76.6752-Week Range$60.08 - $107.44Volume205,387 shsAverage Volume143,692 shsMarket Capitalization$2.39 billionP/E Ratio14.55Dividend YieldN/ABeta1.45 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing immune globulin intravenous; human antithrombin III; Caprylate/Chromatography Purified and 20 nm virus filtration; human coagulation factor IX; human cytomegalovirus immunoglobulin; and human fibrin sealant products. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China. Receive CBPO News and Ratings via Email Sign-up to receive the latest news and ratings for CBPO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBPO Previous Symbol CUSIPN/A Webwww.chinabiologic.com Phone86-10-6598-3111 Debt Debt-to-Equity RatioN/A Current Ratio10.74 Quick Ratio8.85 Price-To-Earnings Trailing P/E Ratio14.55 Forward P/E Ratio21.00 P/E Growth5.26 Sales & Book Value Annual Sales$370.41 million Price / Sales6.44 Cash Flow$4.6525 per share Price / Cash Flow15.48 Book Value$20.05 per share Price / Book3.59 Profitability EPS (Most Recent Fiscal Year)$4.95 Net Income$67.94 million Net Margins15.50% Return on Equity11.44% Return on Assets10.10% Miscellaneous Employees1,912 Outstanding Shares33,130,000Market Cap$2.39 billion OptionableOptionable China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions What is China Biologic Products' stock symbol? China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO." How were China Biologic Products' earnings last quarter? China Biologic Products Holdings Inc (NASDAQ:CBPO) issued its earnings results on Thursday, November, 1st. The biopharmaceutical company reported $0.96 earnings per share for the quarter, missing analysts' consensus estimates of $1.09 by $0.13. The biopharmaceutical company had revenue of $119.10 million for the quarter, compared to analyst estimates of $122 million. China Biologic Products had a return on equity of 11.44% and a net margin of 15.50%. China Biologic Products's revenue for the quarter was up 19.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.32 earnings per share. View China Biologic Products' Earnings History. When is China Biologic Products' next earnings date? China Biologic Products is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for China Biologic Products. What price target have analysts set for CBPO? 4 equities research analysts have issued 12-month price objectives for China Biologic Products' stock. Their predictions range from $84.00 to $105.00. On average, they expect China Biologic Products' share price to reach $95.3333 in the next year. This suggests a possible upside of 32.4% from the stock's current price. View Analyst Price Targets for China Biologic Products. What is the consensus analysts' recommendation for China Biologic Products? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for China Biologic Products in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for China Biologic Products. Has China Biologic Products been receiving favorable news coverage? News coverage about CBPO stock has trended somewhat positive this week, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. China Biologic Products earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. Who are some of China Biologic Products' key competitors? Some companies that are related to China Biologic Products include Qiagen (QGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP) and Regenxbio (RGNX). Who are China Biologic Products' key executives? China Biologic Products' management team includes the folowing people: Mr. Zhijun Tong, Pres & Director (Age 58)Mr. Ming Yang, Chief Financial Officer (Age 46)Mr. Ming Yin, Sr. VP (Age 40)Ms. Zhijing Liu, Corp. VP (Age 64)Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 53) Who are China Biologic Products' major shareholders? China Biologic Products' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (9.20%), Hsbc Holdings PLC (4.48%), York Capital Management Global Advisors LLC (3.52%), Baillie Gifford & Co. (2.66%), Vanguard Group Inc. (2.64%) and Vanguard Group Inc (2.64%). Company insiders that own China Biologic Products stock include David Gao, Sean Shao and Zhijing Cbpo Liu. View Institutional Ownership Trends for China Biologic Products. Which major investors are selling China Biologic Products stock? CBPO stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Baillie Gifford & Co., Macquarie Group Ltd., Comgest Global Investors S.A.S., BlackRock Inc., Renaissance Technologies LLC, Bank of New York Mellon Corp and Point72 Hong Kong Ltd. View Insider Buying and Selling for China Biologic Products. Which major investors are buying China Biologic Products stock? CBPO stock was purchased by a variety of institutional investors in the last quarter, including Hsbc Holdings PLC, Capital World Investors, York Capital Management Global Advisors LLC, Greenwoods Asset Management Ltd, FMR LLC, Kite Lake Capital Management UK LLP, Vanguard Group Inc and Vanguard Group Inc.. View Insider Buying and Selling for China Biologic Products. How do I buy shares of China Biologic Products? Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is China Biologic Products' stock price today? One share of CBPO stock can currently be purchased for approximately $72.02. How big of a company is China Biologic Products? China Biologic Products has a market capitalization of $2.39 billion and generates $370.41 million in revenue each year. The biopharmaceutical company earns $67.94 million in net income (profit) each year or $4.95 on an earnings per share basis. China Biologic Products employs 1,912 workers across the globe. What is China Biologic Products' official website? The official website for China Biologic Products is http://www.chinabiologic.com. How can I contact China Biologic Products? China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected] MarketBeat Community Rating for China Biologic Products (NASDAQ CBPO)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 291 (Vote Outperform)Underperform Votes: 353 (Vote Underperform)Total Votes: 644MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/17/2018 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?